𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Levodopa unresponsive symptoms in Parkinson disease

✍ Scribed by Kapil Sethi

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
131 KB
Volume
23
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Levodopa has been the mainstay of symptomatic therapy for Parkinson Disease (PD) for 40 years providing benefit to virtually all patients. Levodopa therapy results in improved activities of daily living, enhanced quality of life, and improved mortality. However, the long-term use of levodopa is associated with the development of motor fluctuations and dyskinesia. In addition, levodopa therapy has further limitations. It has little or no effect on certain motor features (e.g. gait and balance dysfunction) and a non-motor symptom complex (autonomic dysfunction, pain syndromes, sleep disorders, mood disturbances, dementia). Further, multiple case reports illustrate the potential of levodopa and other dopaminergic agents to cause or reveal a series of impulse control disorders. This review highlights the levodopa unresponsive symptoms in PD.

πŸ“œ SIMILAR VOLUMES

Parkinson's disease/Parkinson syndromesβ€”
Parkinson's disease/Parkinson syndromesβ€”therapy: Levodopa
πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 249 KB

Three patients with Parlcinson's disease, optimally treated with levodopdcabidopa (LDKD) tablets, but experiencing severe motor fluctuations, were administered a solution of levodopd carbidopalascorbic acid (LCAS) orally at intervals ranging from 30 to 60 minutes. Patients were rated half-hourly to

Levodopa response in early Parkinson's d
Levodopa response in early Parkinson's disease
✍ Robert A. Hauser; Peggy Auinger; David Oakes πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 244 KB πŸ‘ 1 views

## Abstract To further characterize the short‐term levodopa response in early PD, we performed a retrospective analysis of the ELLDOPA study which randomized 361 early PD subjects to placebo, levodopa 150, 300, or 600 mg/day. We evaluated change in UPDRS motor scores (UPDRSm) from baseline to weeks